Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
EARLY_PHASE1
100 participants
INTERVENTIONAL
2013-11-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxytocin's Effects on Face Attentional Processing
NCT04413786
Influence of Oxytocin on Neurophysiological Responses to Live Faces
NCT03272321
Oxytocin Effect on Attention Inhibition
NCT03486925
Understanding Visual Processing After Occipital Stroke
NCT06352086
Studying the Effects of Natural Visual Scene Changes on Typical Adult Visual Perception
NCT05004649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Placebo
Placebo will be given to control group and experimental group as well.
congenital prosopagnosia
Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Placebo
Placebo will be given to control group and experimental group as well.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Placebo
Placebo will be given to control group and experimental group as well.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy (according to a pregnancy test taken by subjects prior to participation)
* a history of asthma or nasal polyps
* cardiac disorders
* hyponatremia
* acute or chronic renal insufficiency
* liver cirrhosis
* neurological disease
* other chronic disease
* dementia, or lack of judgment
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ben-Gurion University of the Negev
OTHER
Soroka University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ilan Shelef
Head of medical imaging at Soroka University Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shelef Ilan, MD
Role: PRINCIPAL_INVESTIGATOR
Soroka University Medical Center
Galia Avidan, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Ben-Gurion University of the Negev
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Soroka medical center
Beersheba, Israel, Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Avidan G, Behrmann M. Functional MRI reveals compromised neural integrity of the face processing network in congenital prosopagnosia. Curr Biol. 2009 Jul 14;19(13):1146-50. doi: 10.1016/j.cub.2009.04.060. Epub 2009 May 28.
Avidan G, Behrmann M. Implicit familiarity processing in congenital prosopagnosia. J Neuropsychol. 2008 Mar;2(1):141-64. doi: 10.1348/174866407x260180.
Avidan G, Hasson U, Malach R, Behrmann M. Detailed exploration of face-related processing in congenital prosopagnosia: 2. Functional neuroimaging findings. J Cogn Neurosci. 2005 Jul;17(7):1150-67. doi: 10.1162/0898929054475145.
Behrmann M, Avidan G, Marotta JJ, Kimchi R. Detailed exploration of face-related processing in congenital prosopagnosia: 1. Behavioral findings. J Cogn Neurosci. 2005 Jul;17(7):1130-49. doi: 10.1162/0898929054475154.
Hasson U, Avidan G, Deouell LY, Bentin S, Malach R. Face-selective activation in a congenital prosopagnosic subject. J Cogn Neurosci. 2003 Apr 1;15(3):419-31. doi: 10.1162/089892903321593135.
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23.
Avidan G, Tanzer M, Hadj-Bouziane F, Liu N, Ungerleider LG, Behrmann M. Selective dissociation between core and extended regions of the face processing network in congenital prosopagnosia. Cereb Cortex. 2014 Jun;24(6):1565-78. doi: 10.1093/cercor/bht007. Epub 2013 Jan 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISF, 384/10
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
sor010712ctil
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.